Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil Whole vs Crushed Tablets PK in cGVHD
NCT07127926Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year and Pharmacokinetics at Day 14. Started Feb 2026; status: recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07127926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07127926.